Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Sperogenix In-licenses Rare Disease Treatment in $124 Million Deal

publication date: Jan 4, 2022

Sperogenix Therapeutics, a Beijing rare disease company, in-licensed China rights to vamorolone for rare disease indications from Switzerland's Santhera in a deal valued at up to $124 million, plus royalties. Initially, Sperogenix will develop the drug in China for Duchenne muscular dystrophy, a genetic disease. Santhera is conducting US tests of the drug, with plans to start a rolling submission in Q1 of 2022. In 2019, Sperogenix was formed by Lilly Asia Ventures and Morningside Venture Capital to bring rare diseases therapies to China. More details....

Stock Symbol: (SIX: SANN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.